-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty -- --…
- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July 18, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company…
-- IMCIVREE now available for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome -- -- First and only FDA-approved therapy that targets…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich der Umgestaltung der Versorgung von Menschen mit seltenen genetischen…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), un'azienda biofarmaceutica in fase commerciale impegnata a cambiare radicalmente l'assistenza delle persone affette da malattie genetiche rare…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), una empresa biofarmacéutica en fase comercial comprometida con la transformación de la atención a las personas que padecen enfermedades genéticas…
BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today…
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich dem Ziel verschrieben hat, die Behandlung von Menschen mit seltenen, genetisch…